First Horizon Advisors, Inc. Pacira Bio Sciences, Inc. Transaction History

First Horizon Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$25.5 - $31.51 $306 - $378	12 Added 2.77%	445 $12,000
Q4 2022 Feb 10, 2023	SELL	$38.19 - $57.45 $114 - $172	-3 Reduced 0.69%	433 $16,000
Q2 2022 Aug 02, 2022	BUY	$51.49 - $81.64 $22,295 - $35,350	433 Added 14433.33%	436 $25,000
Q1 2022 May 10, 2022	SELL	$60.03 - $76.49 $25,992 - $33,120	-433 Reduced 99.31%	3 $0
Q4 2021 Feb 09, 2022	SELL	$47.97 - $62.21 $6,092 - $7,900	-127 Reduced 22.56%	436 $26,000
Q3 2021 Nov 15, 2021	BUY	$54.64 - $61.3 $20,981 - $23,539	384 Added 214.53%	563 $31,000
Q3 2021 Nov 09, 2021	SELL	$54.64 - $61.3 $5,354 - $6,007	-98 Reduced 35.38%	179 $10,000
Q1 2021 May 11, 2021	SELL	$59.31 - $78.82 $5,397 - $7,172	-91 Reduced 24.73%	277 $19,000
Q4 2020 Feb 11, 2021	BUY	$50.47 - $66.26 $8,680 - $11,396	172 Added 87.76%	368 $22,000
Q3 2020 Nov 12, 2020	BUY	$51.97 - $63.0 $10,186 - $12,348	196 New	196 $11,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.